.jpg "Anti-Calnexin Specificity Assay (Array)")
.jpg "Calnexin IHC human Renal Cell Carcinoma (CANX 1543)")
%20SDS-PAGE.jpg "Anti-Calnexin(CANX 1543) SDS-PAGE")
.jpg "Calnexin western blot (kidney lysate CANX 1543)")
..jpg "Calnexin expression PANC1 and MCF7 (WB).")
PDF DatasheetHuman Anti-Calnexin (Endoplasmic Reticulum Marker) Antibody Product Attributes
Calnexin (Endoplasmic Reticulum Marker) Previously Observed Antibody Staining Patterns
Observed Subcellular, Organelle Specific Staining Data:
Anti-CANX antibody staining is expected to be primarily localized to the endoplasmic reticulum.
Observed Antibody Staining Data By Tissue Type:
Variations in Calnexin antibody staining intensity in immunohistochemistry on tissue sections are present across different anatomical locations. An intense signal was observed in cells in the glomeruli in kidney, cells in the molecular layer in cerebellum, cells in the red pulp in spleen, cells in the seminiferous ducts in testis, cells in the tubules in kidney, endothelial cells in the colon, exocrine glandular cells in the pancreas, fibroblasts in skin and mesenchymal tissue, glandular cells in the appendix, breast, colon, duodenum, endometrium, epididymis, fallopian tube, gallbladder, prostate, rectum, salivary gland, seminal vesicle, small intestine, stomach and thyroid gland, glial cells in the caudate nucleus, cerebral cortex and hippocampus, hematopoietic cells in the bone marrow, Leydig cells in the testis, macrophages in lung, melanocytes in skin, myoepithelial cells in the breast, neuronal cells in the caudate nucleus, cerebral cortex and hippocampus, non-germinal center cells in the lymph node and tonsil, peripheral nerve/ganglion in colon, pneumocytes in lung, respiratory epithelial cells in the bronchus and nasopharynx and trophoblastic cells in the placenta. More moderate antibody staining intensity was present in cells in the glomeruli in kidney, cells in the molecular layer in cerebellum, cells in the red pulp in spleen, cells in the seminiferous ducts in testis, cells in the tubules in kidney, endothelial cells in the colon, exocrine glandular cells in the pancreas, fibroblasts in skin and mesenchymal tissue, glandular cells in the appendix, breast, colon, duodenum, endometrium, epididymis, fallopian tube, gallbladder, prostate, rectum, salivary gland, seminal vesicle, small intestine, stomach and thyroid gland, glial cells in the caudate nucleus, cerebral cortex and hippocampus, hematopoietic cells in the bone marrow, Leydig cells in the testis, macrophages in lung, melanocytes in skin, myoepithelial cells in the breast, neuronal cells in the caudate nucleus, cerebral cortex and hippocampus, non-germinal center cells in the lymph node and tonsil, peripheral nerve/ganglion in colon, pneumocytes in lung, respiratory epithelial cells in the bronchus and nasopharynx and trophoblastic cells in the placenta. Low, but measureable presence of Calnexin could be seen inmyocytes in skeletal muscle. We were unable to detect Calnexin in other tissues. Disease states, inflammation, and other physiological changes can have a substantial impact on antibody staining patterns. These measurements were all taken in tissues deemed normal or from patients without known disease.
Observed Antibody Staining Data By Tissue Disease Status:
Tissues from cancer patients, for instance, have their own distinct pattern of Calnexin expression as measured by anti-Calnexin antibody immunohistochemical staining. The average level of expression by tumor is summarized in the table below. The variability row represents patient to patient variability in IHC staining.
| Sample Type | breast cancer | carcinoid | cervical cancer | colorectal cancer | endometrial cancer | glioma | head and neck cancer | liver cancer | lung cancer | lymphoma | melanoma | ovarian cancer | pancreatic cancer | prostate cancer | renal cancer | skin cancer | stomach cancer | testicular cancer | thyroid cancer | urothelial cancer |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal Intensity | +++ | +++ | ++ | +++ | +++ | +++ | +++ | +++ | ++ | +++ | +++ | +++ | +++ | +++ | +++ | ++ | +++ | +++ | +++ | +++ |
| CANX Variability | + | + | +++ | + | + | + | ++ | ++ | ++ | ++ | ++ | ++ | + | + | + | ++ | ++ | ++ | ++ | ++ |
| Calnexin (Endoplasmic Reticulum Marker) General Information | |
|---|---|
| Alternate Names | |
| Calnexin; CANX; CNX; IP90; Major histocompatibility complex class I antigen-binding protein p88; P90 | |
| Molecular Weight | |
| 90kDa | |
| Chromosomal Location | |
| Ships on blue ice. | |
| Curated Database and Bioinformatic Data | |
| Gene Symbol | 821 |
| Entrez Gene ID | CANX |
| UniProt ID(s) | P27824 |
| UniGene ID(s) | Hs567968 |
| COSMIC ID Link(s) | CANX |
| KEGG Gene ID(s) | hsa:821 |
| General Description of Calnexin (Endoplasmic Reticulum Marker). | |
| It recognizes a protein of 90kDa, which is identified as Calnexin. Secretory and transmembrane proteins are synthesized on polysomes and translocate into the endoplasmic reticulum (ER) where they are often modified by the formation of disulfide bonds, amino-linked glycosylation and folding. To help proteins fold properly, the ER contains a pool of molecular chaperones including calnexin. It is a calcium-binding, endoplasmic reticulum (ER)-associated protein that interacts transiently with newly synthesized N-linked glycoproteins, facilitating protein folding and assembly. It may also play a central role in the quality control of protein folding by retaining incorrectly folded protein subunits within the ER for degradation. | |
There are no reviews yet.